PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lysogene, a biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, has appointed Dr. Mark Plavsic, Ph.D., as its new Chief Technical Officer. Dr. Plavsic will be based in Lysogene’s U.S. office in Cambridge, Mass., reporting directly to Karen Aiach, Lysogene’s CEO and founder.
Dr. Plavsic has extensive technical experience across a diverse range of functions, proven knowledge of quality compliance and regulatory requirements, and strong business and leadership skills gained from over 30 years of experience working in North America, Europe and Australasia. His industry expertise will help support and advance Lysogene’s manufacturing and CMC operations during development and commercialization phases.
“We are excited to have Dr. Plavsic join our company and help us fine tune our manufacturing strategy and operations which will be key to expanding our business,” said CEO Karen Aiach. “With his impressive technical and operational experience in biotechnology and pharmaceuticals across three different continents, Dr. Plavsic will be an invaluable asset to Lysogene, and we look forward to welcoming him on board.”
“I am delighted to be joining Lysogene and contributing to the development of the company’s pipeline of gene therapy programs. I am eager to support and further the company’s mission of finding treatments for neurodegenerative diseases and other rare conditions, and create a positive impact on patients’ lives,” said Dr. Plavsic.
Most recently, Dr. Plavsic served as Head of Process Development and Manufacturing at Torque Therapeutics, leading multiple functions including process and analytics development and ensuring quality controls and design across manufacturing. Prior to that Dr. Plavsic held multiple positions with Sanofi Genzyme, Astra Zeneca ad Invitrogen Corporation.
Dr. Plavsic received his Ph.D. in Virology and Molecular Cell Biology, M.S. in Virology and Immunology, and Doctor of Veterinary Medicine degree from the University of Belgrade in Yugoslavia. He has a Board certification in Microbiology, subspecialty Virology from the American College of Veterinary Microbiologists.
Lysogene is a clinical-stage biotechnology company pioneering in the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a unique platform and network, with lead products in Mucopolysaccharidosis Type A (Sanfilippo A) and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases.
For more information www.lysogene.com.